Literature DB >> 15198967

Safety of statins: focus on clinical pharmacokinetics and drug interactions.

Stefano Bellosta1, Rodolfo Paoletti, Alberto Corsini.   

Abstract

Statin monotherapy is generally well tolerated, with a low frequency of adverse events. The most important adverse effects associated with statins are myopathy and an asymptomatic increase in hepatic transaminases, both of which occur infrequently. Because statins are prescribed on a long-term basis, however, possible interactions with other drugs deserve particular attention, as many patients will typically receive pharmacological therapy for concomitant conditions during the course of statin treatment. This review summarizes the pharmacokinetic properties of statins and emphasizes their clinically relevant drug interactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198967     DOI: 10.1161/01.CIR.0000131519.15067.1f

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  146 in total

Review 1.  Pharmacokinetic interactions with thiazolidinediones.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.

Authors:  Tuire Tirkkonen; Anna Ryynänen; Tero Vahlberg; Kerttu Irjala; Timo Klaukka; Risto Huupponen; Kari Laine
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 3.  Genetics and personalized medicine--a role in statin therapy?

Authors:  Jaideep Patel; Thura Abd; Roger S Blumenthal; Khurram Nasir; H Robert Superko
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

4.  Statin use and risk of prostate cancer: results from a population-based epidemiologic study.

Authors:  Ilir Agalliu; Claudia A Salinas; Philip D Hansten; Elaine A Ostrander; Janet L Stanford
Journal:  Am J Epidemiol       Date:  2008-06-12       Impact factor: 4.897

5.  Statin adjunctive therapy shortens the duration of TB treatment in mice.

Authors:  Noton K Dutta; Natalie Bruiners; Michael L Pinn; Matthew D Zimmerman; Brendan Prideaux; Véronique Dartois; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2016-02-21       Impact factor: 5.790

6.  Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.

Authors:  C Minichsdorfer; M Hohenegger
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

7.  More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.

Authors:  Ida Robertsen; Anders Asberg; Tone Granseth; Nils Tore Vethe; Fatemeh Akhlaghi; Mwlod Ghareeb; Espen Molden; Morten Reier-Nilsen; Hallvard Holdaas; Karsten Midtvedt
Journal:  Transplantation       Date:  2014-06-27       Impact factor: 4.939

8.  Comparative analysis of the gut microbiota in distinct statin response patients in East China.

Authors:  Baoqing Sun; Luming Li; Xinfu Zhou
Journal:  J Microbiol       Date:  2018-11-27       Impact factor: 3.422

Review 9.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 10.  Rosuvastatin in elderly patients.

Authors:  Michael H Davidson
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.